Nutrition Redefined: Harnessing Genetics for Personalized Wellness

FDA Clears FoundationOne Liquid CDx for Identifying BRCA-Mutated mCRPC Patients Eligible for Janssen's Akeega

ACT Genomics and LSI Medience Forge Strategic Partnership to Advance in the Japanese Market

Key Components of Precision Prevention for Breast Cancer

Advancing Cervical Cancer Screening: The Scope of Digital Cytology

"Pfizer Taps Novartis Executive to Succeed Retiring Suneet Varma as Oncology Commercial Chief"

Sanofi Invests $40M in Vigil Neuroscience, Securing Exclusive License Option to TREM2 Program

Zydus and Dr. Reddy’s Collaborate to Co-Market Pertuzumab Biosimilar, Vital for Breast Cancer Treatment in India

Velsera Launches CGW Plus: Advancing Genetic Sequence Data Analysis & Reporting

HER2DX® Genomic Test Shows Promise in HER2-Positive Advanced Gastric Cancer

FDA Grants CLIA Waiver to Cepheid for Xpert® HCV

AFMC Launches Advanced Genome Sequencing Lab in Pune

Novo Nordisk Acquires 2seventy's Hemophilia A Program and Gene Editing Technology

Roche Broadens Availability of Cervical Cancer Screening Tools with Two New WHO Prequalification Designations, Including HPV Self-Collection

BD Launches New Research Tool to Study Cells Crucial in Cancer and Infectious Diseases

Home
/
update
/
details

C-Path and Centogene Forge Alliance to Propel Drug Development for Lysosomal Diseases

NextEdge Admin

20 Jun 2024

1 min 48 sec

The Critical Path Institute (C-Path) and Centogene have entered into a memorandum of understanding (MOU) to establish a strategic partnership aimed at advancing drug development for rare lysosomal diseases. This collaboration will focus on several key areas, including enhancing data quality and integration for disorders such as Niemann-Pick disease type C, Gaucher disease types 2 and 3, and mucopolysaccharidosis type II. Centogene will contribute genetic testing services for clinical trials and observational studies, along with sample analysis reporting through its CentoCloud platform. Additionally, limited access to Centogene's Biodatabank will facilitate the analysis of patient data from the Critical Path for Lysosomal Diseases (CPLD) Consortium projects.

The MOU also outlines joint branding efforts to leverage the strengths of both organizations in addressing the challenges of lysosomal disease research and drug development. Krista Casazza, scientific director of the CPLD Consortium, highlighted the potential of this partnership to combine expertise and resources effectively.

Earlier in the year, Centogene partnered with the Michael J. Fox Foundation to explore genetic risk factors associated with Parkinson's disease, underscoring its commitment to advancing genetic insights across various diseases.